Scienture Holdings, Inc. (SCNX) Stock Ticker
SCNX right now
Market factors today
Unlock the full SCNX picture
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
SCNX stock facts
| Ticker symbol | SCNX |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Market cap | $11.0M |
| CEO | Shankar Hariharan |
| Employees | 9 |
| Headquarters | Commack, NY, US |
| IPO date | 2014-02-06 |
| Website | scienture.com |
What you can see for SCNX on Tickr
Live SCNX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SCNX report.
Rankings
FAQ
What is the ticker symbol for Scienture Holdings, Inc.?
The ticker symbol for Scienture Holdings, Inc. is SCNX, listed on the NASDAQ Capital Market.
What is SCNX?
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk…